18.12
price up icon3.48%   0.61
 
loading
Precedente Chiudi:
$17.51
Aprire:
$19.24
Volume 24 ore:
4.58M
Relative Volume:
1.75
Capitalizzazione di mercato:
$2.29B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-8.9703
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
-2.63%
1M Prestazione:
-11.70%
6M Prestazione:
+33.53%
1 anno Prestazione:
+51.76%
Intervallo 1D:
Value
$17.64
$20.89
Intervallo di 1 settimana:
Value
$17.26
$20.89
Portata 52W:
Value
$6.78
$23.56

10 X Genomics Inc Stock (TXG) Company Profile

Name
Nome
10 X Genomics Inc
Name
Telefono
(925) 401-7300
Name
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Name
Dipendente
1,306
Name
Cinguettio
@10xgenomics
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
TXG's Discussions on Twitter

Compare TXG vs VEEV, TEM, BTSG, HQY, DOCS

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Health Information Services icon
TXG
10 X Genomics Inc
18.12 2.22B 631.73M -239.78M -33.45M -2.02
Health Information Services icon
VEEV
Veeva Systems Inc
174.11 28.27B 3.08B 860.33M 1.35B 5.1463
Health Information Services icon
TEM
Tempus Ai Inc
51.95 9.03B 803.32M -709.10M -212.68M -7.8003
Health Information Services icon
BTSG
Brightspring Health Services Inc
38.86 6.82B 11.99B 24.18M 234.31M 0.2956
Health Information Services icon
HQY
Healthequity Inc
73.88 6.25B 1.15B 96.70M -161.99M 1.09
Health Information Services icon
DOCS
Doximity Inc
25.02 4.56B 550.17M 201.35M 232.07M 1.00

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-12-11 Downgrade Citigroup Buy → Neutral
2025-12-02 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-09-11 Iniziato Piper Sandler Neutral
2025-02-13 Downgrade Leerink Partners Outperform → Market Perform
2024-09-03 Iniziato Leerink Partners Outperform
2024-07-22 Aggiornamento Jefferies Hold → Buy
2024-07-18 Downgrade JP Morgan Overweight → Neutral
2024-07-10 Downgrade Deutsche Bank Buy → Hold
2024-06-27 Downgrade Wolfe Research Outperform → Peer Perform
2024-06-25 Downgrade Guggenheim Buy → Neutral
2024-06-03 Ripresa Jefferies Hold
2024-05-01 Downgrade TD Cowen Buy → Hold
2023-12-14 Iniziato Guggenheim Buy
2023-12-13 Iniziato Wolfe Research Outperform
2023-12-12 Aggiornamento BofA Securities Underperform → Neutral
2023-07-05 Ripresa JP Morgan Overweight
2023-05-10 Iniziato Barclays Overweight
2023-03-31 Iniziato Stephens Overweight
2023-02-02 Iniziato UBS Neutral
2022-12-14 Iniziato Deutsche Bank Buy
2022-08-18 Downgrade Goldman Neutral → Sell
2022-07-25 Iniziato Canaccord Genuity Buy
2022-07-15 Downgrade BofA Securities Neutral → Underperform
2022-07-15 Downgrade William Blair Outperform → Mkt Perform
2021-10-15 Ripresa Cowen Outperform
2021-09-14 Downgrade BofA Securities Buy → Neutral
2021-03-15 Iniziato William Blair Outperform
2020-12-02 Iniziato Goldman Neutral
2020-09-09 Iniziato Morgan Stanley Overweight
2020-07-10 Iniziato Stifel Buy
2020-03-05 Iniziato Guggenheim Buy
2020-01-07 Iniziato Citigroup Buy
2019-10-07 Iniziato BofA/Merrill Buy
2019-10-07 Iniziato Cowen Outperform
2019-10-07 Iniziato JP Morgan Overweight
2019-09-24 Iniziato Evercore ISI Outperform
Mostra tutto

10 X Genomics Inc Borsa (TXG) Ultime notizie

pulisher
12:53 PM

Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus

12:53 PM
pulisher
Feb 13, 2026

Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga

Feb 13, 2026
pulisher
Feb 13, 2026

Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz

Feb 13, 2026
pulisher
Feb 13, 2026

10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity - Investing.com

Feb 13, 2026
pulisher
Feb 13, 2026

10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity By Investing.com - Investing.com India

Feb 13, 2026
pulisher
Feb 13, 2026

10x Genomics (NASDAQ:TXG) Shares Gap Up on Earnings Beat - MarketBeat

Feb 13, 2026
pulisher
Feb 13, 2026

10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026
pulisher
Feb 13, 2026

10x Genomics Q4 Earnings Call Highlights - MarketBeat

Feb 13, 2026
pulisher
Feb 13, 2026

10x Genomics, Inc. SEC 10-K Report - TradingView

Feb 13, 2026
pulisher
Feb 13, 2026

10x Genomics: Fourth Quarter Financial Overview - Bitget

Feb 13, 2026
pulisher
Feb 13, 2026

10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpass - GuruFocus

Feb 13, 2026
pulisher
Feb 12, 2026

Can 10x Genomics Inc. stock outperform in a bear market2025 Top Decliners & High Return Trade Opportunity Guides - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics (TXG) Q4 2025 Earnings Transcript - AOL.com

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics (TXG) Surpasses Q4 Revenue Expectations - GuruFocus

Feb 12, 2026
pulisher
Feb 12, 2026

Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 12, 2026
pulisher
Feb 12, 2026

Earnings call transcript: 10x Genomics beats Q4 2025 EPS forecast By Investing.com - Investing.com India

Feb 12, 2026
pulisher
Feb 12, 2026

Earnings call transcript: 10x Genomics beats Q4 2025 EPS forecast - Investing.com

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025 - Finviz

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics Q4 2025 Financial Results: Loss Narrows, Revenue at $166MNews and Statistics - IndexBox

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics: Q4 Earnings Snapshot - kare11.com

Feb 12, 2026
pulisher
Feb 12, 2026

Earnings Flash (TXG) 10x Genomics, Inc. Reports Q4 Revenue $166.0M, vs. FactSet Est of $159.7M - marketscreener.com

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics Earnings Report: Q4 Overview - Benzinga

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics (NASDAQ: TXG) narrows 2025 losses and guides to modest 2026 growth - Stock Titan

Feb 12, 2026
pulisher
Feb 12, 2026

10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 - PR Newswire

Feb 12, 2026
pulisher
Feb 12, 2026

10X Genomics faces earnings test as new pricing strategy debuts By Investing.com - Investing.com Nigeria

Feb 12, 2026
pulisher
Feb 12, 2026

10X Genomics faces earnings test as new pricing strategy debuts - Investing.com

Feb 12, 2026
pulisher
Feb 11, 2026

What makes 10x Genomics Inc. stock attractive todayQuarterly Profit Report & Free Community Consensus Stock Picks - mfd.ru

Feb 11, 2026
pulisher
Feb 11, 2026

10x Genomics Earnings Preview - Sahm

Feb 11, 2026
pulisher
Feb 10, 2026

10x Genomics Earnings Preview: Revenue Forecast, Analyst Estimates & Stock OutlookNews and Statistics - IndexBox

Feb 10, 2026
pulisher
Feb 10, 2026

10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - Finviz

Feb 10, 2026
pulisher
Feb 08, 2026

10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN

Feb 08, 2026
pulisher
Feb 06, 2026

IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 190,059 Shares of 10x Genomics $TXG - MarketBeat

Feb 06, 2026
pulisher
Feb 05, 2026

Best Genetic Sequencing Stocks to Buy in 2026 and How to Invest in Them - The Motley Fool

Feb 05, 2026
pulisher
Feb 05, 2026

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Finviz

Feb 05, 2026
pulisher
Feb 05, 2026

10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Feb 05, 2026
pulisher
Feb 04, 2026

PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology - Finviz

Feb 04, 2026
pulisher
Feb 04, 2026

Pharosai and 10X Genomics Partner to Transform Cancer Research with Ai and Spatial Biology - marketscreener.com

Feb 04, 2026
pulisher
Feb 04, 2026

PharosAI and 10x Genomics Partner to Transform Cancer Research w - GuruFocus

Feb 04, 2026
pulisher
Feb 04, 2026

10x Genomics (NASDAQ:TXG) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Feb 04, 2026
pulisher
Feb 03, 2026

Fundamentals Check: Can 10x Genomics Inc sustain its profitabilityBull Run & Daily Profit Focused Screening - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 02, 2026

Foundations Investment Advisors LLC Takes Position in 10x Genomics $TXG - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

10x Genomics $TXG Holdings Decreased by Federated Hermes Inc. - MarketBeat

Feb 02, 2026
pulisher
Feb 01, 2026

Universal Beteiligungs und Servicegesellschaft mbH Purchases New Shares in 10x Genomics $TXG - MarketBeat

Feb 01, 2026
pulisher
Feb 01, 2026

AlphaQuest LLC Increases Holdings in 10x Genomics $TXG - MarketBeat

Feb 01, 2026
pulisher
Jan 29, 2026

Is 10x Genomics Inc. still a buy after recent gainsPortfolio Profit Report & AI Enhanced Trading Signals - Mfd.ru

Jan 29, 2026
pulisher
Jan 28, 2026

Stock Report: Will 10x Genomics Inc. outperform its industry peersJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru

Jan 28, 2026
pulisher
Jan 27, 2026

Breaking Down 10x Genomics: 13 Analysts Share Their Views - Benzinga

Jan 27, 2026
pulisher
Jan 27, 2026

10x Genomics (NASDAQ:TXG) Given New $20.00 Price Target at Leerink Partners - MarketBeat

Jan 27, 2026
pulisher
Jan 24, 2026

10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected - simplywall.st

Jan 24, 2026

10 X Genomics Inc Azioni (TXG) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.39
price up icon 4.14%
$20.66
price down icon 8.14%
$38.94
price down icon 1.34%
health_information_services WAY
$22.41
price up icon 3.08%
$25.02
price up icon 1.25%
Capitalizzazione:     |  Volume (24 ore):